New Phase 3 trial: ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma — Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Why now
Thesis: Phase 3 registration for Zelgen neuroendocrine carcinoma drug
Catalyst to watch: Enrollment progress or interim analysis
Main risk: Sponsor not in allowed ticker set
Why it matters
Phase 3 registration for a Zelgen neuroendocrine carcinoma drug; sponsor not in allowed ticker set.
Details
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd; Status: Not Yet Recruiting; Conditions: Neuroendocrine Carcinomas (NEC); Interventions: ZG005 for Injection, Etoposide Injection, Cisplatin Injection; Enrollment: 440 (estimated); First posted: 2026-09-22; NCT: NCT07833839
Related assets & topics
HealthcareSources
- clinicaltrials · 2026-09-22 12:00 UTC